STL Index for: Karla Machlab
Risankizumab in Adults with Psoriatic Arthritis
Explore risankizumab for Psoriatic arthritis: Beyond ACR, it significantly improves enthesitis, dactylitis, and QoL scores like HAQ-DI. Promising in efficacy and safety, with full 208-week study results anticipated for a complete understanding.
